Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

Hua Xin Liao, Mattia Bonsignori, S. Munir Alam, Jason S. McLellan, Georgia D. Tomaras, M. Anthony Moody, Daniel M. Kozink, Kwan Ki Hwang, Xi Chen, Chun Yen Tsao, Pinghuang Liu, Xiaozhi Lu, Robert J. Parks, David C. Montefiori, Guido Ferrari, Justin Pollara, Mangala Rao, Kristina K. Peachman, Sampa Santra, Norman L. LetvinNicos Karasavvas, Zhi Yong Yang, Kaifan Dai, Marie Pancera, Jason Gorman, Kevin Wiehe, Nathan I. Nicely, Supachai Rerks-Ngarm, Sorachai Nitayaphan, Jaranit Kaewkungwal, Punnee Pitisuttithum, James Tartaglia, Faruk Sinangil, Jerome H. Kim, Nelson L. Michael, Thomas B. Kepler, Peter D. Kwong, John R. Mascola, Gary J. Nabel, Abraham Pinter, Susan Zolla-Pazner, Barton F. Haynes

Research output: Contribution to journalArticle

Abstract

The RV144 HIV-1 trial of the canary pox vector (ALVAC-HIV) plus the gp120 AIDSVAX B/E vaccine demonstrated an estimated efficacy of 31%, which correlated directly with antibodies to HIV-1 envelope variable regions 1 and 2 (V1-V2). Genetic analysis of trial viruses revealed increased vaccine efficacy against viruses matching the vaccine strain at V2 residue 169. Here, we isolated four V2 monoclonal antibodies from RV144 vaccinees that recognize residue 169, neutralize laboratory-adapted HIV-1, and mediate killing of field-isolate HIV-1-infected CD4+ T cells. Crystal structures of two of the V2 antibodies demonstrated that residue 169 can exist within divergent helical and loop conformations, which contrasted dramatically with the β strand conformation previously observed with a broadly neutralizing antibody PG9. Thus, RV144 vaccine-induced immune pressure appears to target a region that may be both sequence variable and structurally polymorphic. Variation may signal sites of HIV-1 envelope vulnerability, providing vaccine designers with new options.

Original languageEnglish (US)
Pages (from-to)176-186
Number of pages11
JournalImmunity
Volume38
Issue number1
DOIs
StatePublished - Jan 24 2013
Externally publishedYes

Fingerprint

HIV-1
Vaccines
Pressure
Antibodies
Proteins
Canaries
Viruses
Neutralizing Antibodies
Monoclonal Antibodies
T-Lymphocytes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases
  • Immunology

Cite this

Liao, H. X., Bonsignori, M., Alam, S. M., McLellan, J. S., Tomaras, G. D., Moody, M. A., ... Haynes, B. F. (2013). Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. Immunity, 38(1), 176-186. https://doi.org/10.1016/j.immuni.2012.11.011

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. / Liao, Hua Xin; Bonsignori, Mattia; Alam, S. Munir; McLellan, Jason S.; Tomaras, Georgia D.; Moody, M. Anthony; Kozink, Daniel M.; Hwang, Kwan Ki; Chen, Xi; Tsao, Chun Yen; Liu, Pinghuang; Lu, Xiaozhi; Parks, Robert J.; Montefiori, David C.; Ferrari, Guido; Pollara, Justin; Rao, Mangala; Peachman, Kristina K.; Santra, Sampa; Letvin, Norman L.; Karasavvas, Nicos; Yang, Zhi Yong; Dai, Kaifan; Pancera, Marie; Gorman, Jason; Wiehe, Kevin; Nicely, Nathan I.; Rerks-Ngarm, Supachai; Nitayaphan, Sorachai; Kaewkungwal, Jaranit; Pitisuttithum, Punnee; Tartaglia, James; Sinangil, Faruk; Kim, Jerome H.; Michael, Nelson L.; Kepler, Thomas B.; Kwong, Peter D.; Mascola, John R.; Nabel, Gary J.; Pinter, Abraham; Zolla-Pazner, Susan; Haynes, Barton F.

In: Immunity, Vol. 38, No. 1, 24.01.2013, p. 176-186.

Research output: Contribution to journalArticle

Liao, HX, Bonsignori, M, Alam, SM, McLellan, JS, Tomaras, GD, Moody, MA, Kozink, DM, Hwang, KK, Chen, X, Tsao, CY, Liu, P, Lu, X, Parks, RJ, Montefiori, DC, Ferrari, G, Pollara, J, Rao, M, Peachman, KK, Santra, S, Letvin, NL, Karasavvas, N, Yang, ZY, Dai, K, Pancera, M, Gorman, J, Wiehe, K, Nicely, NI, Rerks-Ngarm, S, Nitayaphan, S, Kaewkungwal, J, Pitisuttithum, P, Tartaglia, J, Sinangil, F, Kim, JH, Michael, NL, Kepler, TB, Kwong, PD, Mascola, JR, Nabel, GJ, Pinter, A, Zolla-Pazner, S & Haynes, BF 2013, 'Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2', Immunity, vol. 38, no. 1, pp. 176-186. https://doi.org/10.1016/j.immuni.2012.11.011
Liao, Hua Xin ; Bonsignori, Mattia ; Alam, S. Munir ; McLellan, Jason S. ; Tomaras, Georgia D. ; Moody, M. Anthony ; Kozink, Daniel M. ; Hwang, Kwan Ki ; Chen, Xi ; Tsao, Chun Yen ; Liu, Pinghuang ; Lu, Xiaozhi ; Parks, Robert J. ; Montefiori, David C. ; Ferrari, Guido ; Pollara, Justin ; Rao, Mangala ; Peachman, Kristina K. ; Santra, Sampa ; Letvin, Norman L. ; Karasavvas, Nicos ; Yang, Zhi Yong ; Dai, Kaifan ; Pancera, Marie ; Gorman, Jason ; Wiehe, Kevin ; Nicely, Nathan I. ; Rerks-Ngarm, Supachai ; Nitayaphan, Sorachai ; Kaewkungwal, Jaranit ; Pitisuttithum, Punnee ; Tartaglia, James ; Sinangil, Faruk ; Kim, Jerome H. ; Michael, Nelson L. ; Kepler, Thomas B. ; Kwong, Peter D. ; Mascola, John R. ; Nabel, Gary J. ; Pinter, Abraham ; Zolla-Pazner, Susan ; Haynes, Barton F. / Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. In: Immunity. 2013 ; Vol. 38, No. 1. pp. 176-186.
@article{d75fdb74f2a945eaa9e759f705ef750a,
title = "Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2",
abstract = "The RV144 HIV-1 trial of the canary pox vector (ALVAC-HIV) plus the gp120 AIDSVAX B/E vaccine demonstrated an estimated efficacy of 31{\%}, which correlated directly with antibodies to HIV-1 envelope variable regions 1 and 2 (V1-V2). Genetic analysis of trial viruses revealed increased vaccine efficacy against viruses matching the vaccine strain at V2 residue 169. Here, we isolated four V2 monoclonal antibodies from RV144 vaccinees that recognize residue 169, neutralize laboratory-adapted HIV-1, and mediate killing of field-isolate HIV-1-infected CD4+ T cells. Crystal structures of two of the V2 antibodies demonstrated that residue 169 can exist within divergent helical and loop conformations, which contrasted dramatically with the β strand conformation previously observed with a broadly neutralizing antibody PG9. Thus, RV144 vaccine-induced immune pressure appears to target a region that may be both sequence variable and structurally polymorphic. Variation may signal sites of HIV-1 envelope vulnerability, providing vaccine designers with new options.",
author = "Liao, {Hua Xin} and Mattia Bonsignori and Alam, {S. Munir} and McLellan, {Jason S.} and Tomaras, {Georgia D.} and Moody, {M. Anthony} and Kozink, {Daniel M.} and Hwang, {Kwan Ki} and Xi Chen and Tsao, {Chun Yen} and Pinghuang Liu and Xiaozhi Lu and Parks, {Robert J.} and Montefiori, {David C.} and Guido Ferrari and Justin Pollara and Mangala Rao and Peachman, {Kristina K.} and Sampa Santra and Letvin, {Norman L.} and Nicos Karasavvas and Yang, {Zhi Yong} and Kaifan Dai and Marie Pancera and Jason Gorman and Kevin Wiehe and Nicely, {Nathan I.} and Supachai Rerks-Ngarm and Sorachai Nitayaphan and Jaranit Kaewkungwal and Punnee Pitisuttithum and James Tartaglia and Faruk Sinangil and Kim, {Jerome H.} and Michael, {Nelson L.} and Kepler, {Thomas B.} and Kwong, {Peter D.} and Mascola, {John R.} and Nabel, {Gary J.} and Abraham Pinter and Susan Zolla-Pazner and Haynes, {Barton F.}",
year = "2013",
month = "1",
day = "24",
doi = "10.1016/j.immuni.2012.11.011",
language = "English (US)",
volume = "38",
pages = "176--186",
journal = "Immunity",
issn = "1074-7613",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

AU - Liao, Hua Xin

AU - Bonsignori, Mattia

AU - Alam, S. Munir

AU - McLellan, Jason S.

AU - Tomaras, Georgia D.

AU - Moody, M. Anthony

AU - Kozink, Daniel M.

AU - Hwang, Kwan Ki

AU - Chen, Xi

AU - Tsao, Chun Yen

AU - Liu, Pinghuang

AU - Lu, Xiaozhi

AU - Parks, Robert J.

AU - Montefiori, David C.

AU - Ferrari, Guido

AU - Pollara, Justin

AU - Rao, Mangala

AU - Peachman, Kristina K.

AU - Santra, Sampa

AU - Letvin, Norman L.

AU - Karasavvas, Nicos

AU - Yang, Zhi Yong

AU - Dai, Kaifan

AU - Pancera, Marie

AU - Gorman, Jason

AU - Wiehe, Kevin

AU - Nicely, Nathan I.

AU - Rerks-Ngarm, Supachai

AU - Nitayaphan, Sorachai

AU - Kaewkungwal, Jaranit

AU - Pitisuttithum, Punnee

AU - Tartaglia, James

AU - Sinangil, Faruk

AU - Kim, Jerome H.

AU - Michael, Nelson L.

AU - Kepler, Thomas B.

AU - Kwong, Peter D.

AU - Mascola, John R.

AU - Nabel, Gary J.

AU - Pinter, Abraham

AU - Zolla-Pazner, Susan

AU - Haynes, Barton F.

PY - 2013/1/24

Y1 - 2013/1/24

N2 - The RV144 HIV-1 trial of the canary pox vector (ALVAC-HIV) plus the gp120 AIDSVAX B/E vaccine demonstrated an estimated efficacy of 31%, which correlated directly with antibodies to HIV-1 envelope variable regions 1 and 2 (V1-V2). Genetic analysis of trial viruses revealed increased vaccine efficacy against viruses matching the vaccine strain at V2 residue 169. Here, we isolated four V2 monoclonal antibodies from RV144 vaccinees that recognize residue 169, neutralize laboratory-adapted HIV-1, and mediate killing of field-isolate HIV-1-infected CD4+ T cells. Crystal structures of two of the V2 antibodies demonstrated that residue 169 can exist within divergent helical and loop conformations, which contrasted dramatically with the β strand conformation previously observed with a broadly neutralizing antibody PG9. Thus, RV144 vaccine-induced immune pressure appears to target a region that may be both sequence variable and structurally polymorphic. Variation may signal sites of HIV-1 envelope vulnerability, providing vaccine designers with new options.

AB - The RV144 HIV-1 trial of the canary pox vector (ALVAC-HIV) plus the gp120 AIDSVAX B/E vaccine demonstrated an estimated efficacy of 31%, which correlated directly with antibodies to HIV-1 envelope variable regions 1 and 2 (V1-V2). Genetic analysis of trial viruses revealed increased vaccine efficacy against viruses matching the vaccine strain at V2 residue 169. Here, we isolated four V2 monoclonal antibodies from RV144 vaccinees that recognize residue 169, neutralize laboratory-adapted HIV-1, and mediate killing of field-isolate HIV-1-infected CD4+ T cells. Crystal structures of two of the V2 antibodies demonstrated that residue 169 can exist within divergent helical and loop conformations, which contrasted dramatically with the β strand conformation previously observed with a broadly neutralizing antibody PG9. Thus, RV144 vaccine-induced immune pressure appears to target a region that may be both sequence variable and structurally polymorphic. Variation may signal sites of HIV-1 envelope vulnerability, providing vaccine designers with new options.

UR - http://www.scopus.com/inward/record.url?scp=84872809067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872809067&partnerID=8YFLogxK

U2 - 10.1016/j.immuni.2012.11.011

DO - 10.1016/j.immuni.2012.11.011

M3 - Article

C2 - 23313589

AN - SCOPUS:84872809067

VL - 38

SP - 176

EP - 186

JO - Immunity

JF - Immunity

SN - 1074-7613

IS - 1

ER -